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Abstract
In spite of their major impact in cancer therapy, immune checkpoint inhibitors are considered to be contraindicated in liver
transplant recipients due to fear of rejection and fatal liver failure. Nevertheless, an increasing number of instances of liver
transplant recipients treated with checkpoint inhibitors is being published. We reviewed the reports on 14 known cases of
liver transplant recipients who underwent treatment with checkpoint inhibitors and discuss factors likely to determine
susceptibility to organ rejection including the choice of the agent and the immunosuppression employed, the assessment of
Programmed cell death 1 ligand 1 (PD-L1) status in liver graft biopsies, and the time of treatment initiation.
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The approach to systemic treatment of many malignan-
cies has been changed drastically by the recent advent
of immune checkpoint inhibitors (CPIs).1 These agents
are designed to enhance the tumour-specific activity of
immune cells and do not possess intrinsic cytotoxicity;
their mechanism of action explains the lack of adverse
events typically associated with the use of conventional
chemotherapy, however it also accounts for the fre-
quent occurrence of autoimmune-related unwanted
effects associated with their use as well as the reluctance
to use them in transplant recipients.2
Owing to long-term immunosuppression, organ
transplant recipients are an at-risk population for the
development of a wide spectrum of malignancies com-
prising melanoma and haematological cancers.3 This
risk is further increased in patients who underwent
transplantation due to hepatocellular carcinoma
(HCC) due to a post-transplant recurrence risk of
approximately 10% within five years.4,5 Despite this
increased need for effective cancer treatment options,
CPIs are considered as contraindicated in organ trans-
plant recipients for fear of organ rejection.
Nevertheless, due to their potential clinical benefit
CPIs have, since their approval, been used as a salvage
option in a number of transplanted patients. Accounts
of these cases, which at present amount to less than
40 published reports, confirm that organ rejection is a
frequent occurrence in this setting.6–8 However, good
tolerability and signs of significant anticancer efficacy
were observed in some cases.6
As of today, to our knowledge 14 cases of liver trans-
plant recipients who have been treated with immune
CPIs have been published (Table 1). Altogether, liver
graft rejection was reported in four of 14 reported
cases; in three cases with lethal outcome, rejection
occurred within three weeks since the initiation of ther-
apy.9 Overall survival was available in 12 cases and
amounted to a median value of 1.2 months. However,
in four patients showing a response to treatment, sur-
vival ranged between at least four10 and 1811 months.
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Data from these reports are scanty and too hetero-
geneous to draw definitive conclusions on the factors
determining graft rejection; they tell us, however, that
while some patients experience graft loss upon treat-
ment with CPIs, others do not and that, besides indi-
vidual host- and donor-related genetic factors, other
modifiable factors might determine the susceptibility
to organ rejection. We discuss below a possible role
of such factors which include the choice of the agent
and the immunosuppression employed, the availability
of biopsies, and the time of treatment initiation.
Agent used
Out of 14 cases of liver graft recipients treated with
CPIs, all but two patients, who received the cytotoxic
T-lymphocyte-associated Protein 4 (CTLA-4) inhibitor
ipilimumab, underwent treatment with Programmed
cell death 1(PD1)/Programmed cell death 1 ligand
1(PD-L1) blocking agents. Organ rejection was
reported in four out of 10 patients treated with nivolu-
mab or pembrolizumab but in neither of the two
patients treated with ipilimumab, although in these
latter cases immunosuppression was tapered at sub-
therapeutic levels. Data from these reports are
insufficient to draw the conclusion that CTLA4 inhibi-
tors are safer than PD-1/PDL-1 inhibitors in liver
transplant recipients. However, some authors suggest
that the lack of organ rejection during ipilimumab
treatment reflects a predominant role of PD-1 in deter-
mining graft tolerance.8,12 Nevertheless, a recent survey
reported kidney graft rejection occurring under treat-
ment with either CTLA-4 or PD-1 inhibitors.8 There is
therefore, at this time, no evidence supporting the use
of a particular CPI in liver allograft recipients and,
until more data become available, it seems reasonable
that the choice of the agent should be primarily guided
by the data available on effectiveness in the respective
tumour entities.
Liver biopsies
Another relevant point regards the issue of whether
assessment of immune checkpoint regulators in liver
biopsies might serve to predict rejection in the same
way their assessment predict response in some tumour
entities.13 Each of the three available biopsies from
patients with acute graft rejection showed elevated
PD-L1 expression,9,14,15 whereas none of the four biop-
sies available from patients without rejection (including
Table 1. Patients’ characteristics and reported outcome of published case reports on treatment with checkpoint inhibitors in liver
transplant recipients, listed according to publication date.
Patient Reference Malignancy Compound
Transplant to
immunotherapy
in years Response
OS
(months)
Graft
rejection
PD-L1
status status Immunosuppression
1 17 Melanoma Ipilimumab 8 No >5a No N/A N/A Low dose tacrolimus
2 10 Melanoma Ipilimumab 8 Yes >4a No N/A N/A Low dose sirolimus
3 7 HCC Nivolumab 1 Yes 10 No 0% N/A Low dose tacrolimus
4 14 Fibrolamellar
HCC
Nivolumab 4 N/A 1 Yes,
lethal
Positive Positive Sirolimus
5 14 Fibrolamellar
HCC
Nivolumab 3 N/A 1 Yes,
lethal
Positive Positive Tacrolimus
6 9 Melanoma Pembrolizumab N/A N/A N/A Yes,
lethal
N/A N/A Ciclosporine
7 19 HCC Pembrolizumab 8 No 3 No N/A N/A Low dose tacrolimus
8 15 HCC Nivolumab 2.7 No 1.2 No N/A 10% Tacrolimus
9 15 Melanoma Pembrolizumab 5.5 Yes 9.5 No 0% 5% Everolimus, MMF
10 15 HCC Nivolumab 7.8 No 1.1 No 0% N/A Sirolimus, MMF
11 15 HCC Nivolumab 3.7 No 1.3 No 0% 0% Tacrolimus
12 15 HCC Nivolumab 1.2 N/A 0.3 No N/A 0% Tacrolimus
13 15 HCC Nivolumab 1.1 N/A 0.9 Yes 30% 0% N/A
14 11 Melanoma Ipilimumab/
pembrolizumab
6 Yes/yes 18a No N/A N/A Sirolimus
HCC: hepatocellular carcinoma; OS: overall survival; N/A: not available.
PD-L1 or PD1 - status of the transplant liver; MMF: Mycophenolate Mofetil; PD1: Programmed cell death 1; PD-L1: Programmed cell death 1 ligand 1.
aBased on report on response duration.
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a pre-treatment biopsy performed in one of our patients
– Figure 1) showed positive PD-L1 staining. It is there-
fore highly suggestive that PD-L1 expression might pre-
dict graft rejection. However, biopsies from patients
experiencing rejection were reported to be obtained
after initiation of therapy and it cannot be ruled out
that positive PD-L1 staining reflects a consequence of
organ rejection. It seems therefore reasonable to sug-
gest that graft liver biopsies are preformed routinely
prior to therapy with CPI in liver transplant recipients
and that staining for PDL-1 is taken into consideration
for the choice of whether a PD1/PDL-1- or a CTLA4-
blocking agent should be employed.
Immunosuppression
Immunosuppression plays a potentially detrimental
role in determining the efficacy of CPIs, since their
effect requires an intact T-cell response. Whether con-
current steroid treatment counteracts the efficacy of
CPIs in non-transplanted patients is still an issue of
debate, a recent survey suggests that concomitant use
of steroids does not necessarily influence the efficacy of
CPI treatment.16 In addition, immunosuppression did
not prevent response in four patients (cases 1, 3, 8,
and 13, Table 1) and a report has recently shown that
preventive treatment with high-dose steroids, intended
to avoid CPI-mediated rejection, did not prevent a
remarkable response in a kidney transplant recipient.6
Therefore, although reduction of immunosuppression
to sub-therapeutic doses was not associated with
organ rejection,7,10,17 pre-treatment with steroids
could be attempted in the absence of contraindications
and immunosuppression tapered during the course of
treatment whenever possible.
Initiation of treatment
Due to the potentially lethal consequences of organ
rejection, the decision to employ CPIs is usually
delayed until unequivocal signs of therapy failure are
observed during treatment with conventional agents.
Although response to CPIs are expected to occur
soon after treatment initiation (most occurring within
three months of initiation of therapy),18 a delayed onset
of treatment might prevent the efficacy of CPIs to
become evident before untreatable disease progression
or organ dysfunction occur; this might at least in part
account for the dismal survival so far reported for liver
transplant patients undergoing treatment with CPIs
(Table 1). It is therefore advisable that, if CPI treatment
is considered as an option, a close follow-up is per-
formed during first-line conventional treatment to rec-
ognise signs of disease progression early, and that the
decision to initiate treatment with a CPI is taken in a
timely manner.
In summary, the decision to initiate CPI treatment in
liver transplant patients should be made on an individ-
ual basis based on consideration of the patient’s per-
formance status, the potential oncological benefits and
the tentative nature of this possibility. We suggest that
liver biopsies of liver allografts are taken routinely
before treatment initiation and that, if staining for
PD-L1 is detected, initiation of treatment with a
CTL4-blocking agent is considered. Pre-treatment
with steroids can be attempted in the absence of obvi-
ous contraindications, as recently suggested,6 and
immunosuppression progressively tapered under close
surveillance.7 Close follow-up to detect signs of pro-
gression under conventional therapy should trigger a
timely choice to begin CPI treatment.
Finally, it cannot be emphasised enough that at
the present state of knowledge, the decision to treat
transplant recipients with immune CPI is to be con-
sidered as ultima ratio to be weighed against the
possibility of graft loss and fatal organ failure.
However, an accurate account of the above factors in
future reports will contribute to understanding of the
factors determining rejection upon treatment with CPI
and possibly guide the design of appropriate prospect-
ive studies.
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Figure 1. Negative anti-programmed cell death 1 ligand 1 (PD-L1)
staining (100x) of a pretherapeutic liver biopsy from a liver graft
recipient treated with Nivolumab without signs of organ rejection7
(Courtesy Prof. Jens Neumann).
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